EntreMed Inc. / The NASDAQ Stock Market LLC / OVERVIEW EntreMed Inc. / Indicate / K EntreMed Inc. / /
Currency
USD / /
Event
FDA Phase / /
Facility
Medical Center Drive / /
IndustryTerm
Delaware law / prudent resource management / versatile potential therapeutic applications / pharmaceutical / biopharmaceutical industry / potential applications / treatment of cancer / intricate communication networks / chemical entities / chemical entity / /
MedicalCondition
certain diseases / arthritis / rheumatoid arthritis / endometrial cancers / metastatic breast cancer / injury / chronic inflammation / non-small cell lung cancer / human diseases / non-immunosuppressive disease modifying treatment / inflammatory diseases / pancreatic cancer / cancers / leukemia / tumor / acute and chronic inflammation / cancer / disease / different diseases / acute inflammation / cardiovascular disease / diabetes / advanced cancer / diseases / refractory solid tumors / inflammation / /
Organization
U.S. Securities and Exchange Commission / SECURITIES AND EXCHANGE COMMISSION WASHINGTON / D. C. / I.R.S. / FDA / /
Person
Michael M. Tarnow / Kenneth W. Bair / / /
Position
Principal Accountant / Board James S. Burns President & Chief Executive Officer / Senior Vice President / Research & Development / Governor / Director Independence / Executive / Chairman of the Board / /
Product
ovarian/ / ENMD-1198 / ENMD-2076 / active investigational new drug / MKC-1 / /
Dear Valued Shareholder, April 2008 In 2007, EntreMed continued to make progress in advancing its clinical and preclinical development programs, securing additional funding, and strengthening our executive managem